Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials

OBJECTIVES: BUILDER-1 and BUILDER-2 aimed to assess the efficacy and safety of tocilizumab (TCZ) in patients with ankylosing spondylitis (AS). METHODS: BUILDER-1 was a two part, phase II–III parallel-group trial in patients with AS naive to antitumour necrosis factor (aTNF) treatment. Patients in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sieper, Joachim, Porter-Brown, Benjamin, Thompson, Liz, Harari, Olivier, Dougados, Maxime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888605/
https://www.ncbi.nlm.nih.gov/pubmed/23765873
http://dx.doi.org/10.1136/annrheumdis-2013-203559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888605/
https://www.ncbi.nlm.nih.gov/pubmed/23765873
http://dx.doi.org/10.1136/annrheumdis-2013-203559

Ejemplares similares